Mark Ross Middleton

32PUBLICATIONS
243CO-AUTHORS
Innate immunityGene and molecular therapyMolecular targetsCancer geneticsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (32)

|Sep 07, 2026
Anti-CMV IgG titer determines organ-specific protection toward immune checkpoint blockade-induced toxicities.

|Sep 12, 2025
Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients.

Takami Sato, Marcus O Butler, Sophie Piperno-Neumann

|Jul 08, 2025
RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE).

Michael K Wong, Mohammed M Milhem, Joseph J Sacco

|Jun 02, 2025
Preferences for multi-cancer tests (MCTs) in primary care: discrete choice experiments of general practitioners and the general public in England.

John Buckell, Nomalanga Madyiwa, Gail Hayward

|Apr 24, 2025
CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade.

Gusztav Milotay, Martin Little, Robert A Watson

|Mar 19, 2025
Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma.

Reinhard Dummer, Shahneen Sandhu, Wilson H Miller

Pageof 6

Frequent Collaborators

6 joint publications

Benjamin P Fairfax

4 joint publications

Orion Tong

3 joint publications

Victoria Woodcock

3 joint publications

Paolo Antonio Ascierto